首页> 外文会议>Biophotonics and immune responses V >Photodynamic Therapy for Cancer and Activation of Immune Response
【24h】

Photodynamic Therapy for Cancer and Activation of Immune Response

机译:光动力疗法治疗癌症和激活免疫反应

获取原文
获取原文并翻译 | 示例

摘要

Anti-tumor immunity is stimulated after PDT for cancer due to the acute inflammatory response; exposure and presentation of tumor-specific antigens; and induction of heat-shock proteins and other danger signals. Nevertheless effective; powerful tumor-specific immune response in both animal models and also in patients treated with PDT for cancer; is the exception rather than the rule. Research in our laboratory and also in others is geared towards identifying reasons for this sub-optimal immune response and discovering ways of maximizing it. Reasons why the immune response after PDT is less than optimal include the fact that tumor-antigens are considered to be self-like and poorly immunogenic; the tumor-mediated induction of CD4+CD25+foxP3+ regulatory T-cells (T-regs); that are able to inhibit both the priming and the effector phases of the cytotoxic CD8 T-cell anti-tumor response and the defects in dendritic cell maturation; activation and antigen-presentation that may also occur. Alternatively-activated macrophages (M2) have also been implicated. Strategies to overcome these immune escape mechanisms employed by different tumors include combination regimens using PDT and immunostimulating treatments such as products obtained from pathogenic microorganisms against which mammals have evolved recognition systems such as PAMPs and toll-like receptors (TLR). This paper will cover the use of CpG oligonucleotides (a TLR9 agonist found in bacterial DNA) to reverse dendritic cell dysfunction and methods to remove the immune suppressor effects of T-regs that are under active study.
机译:由于急性炎症反应,PDT治疗后可激发抗肿瘤免疫力。肿瘤特异性抗原的暴露和呈递;以及诱导热激蛋白和其他危险信号。尽管有效;在两种动物模型中以及在接受PDT治疗的癌症患者中都有强大的肿瘤特异性免疫反应;是例外而不是规则。我们实验室以及其他实验室的研究旨在确定这种次优免疫反应的原因,并寻求使其最大化的方法。 PDT后免疫反应不理想的原因包括以下事实:肿瘤抗原被认为是自体的且免疫原性差;肿瘤介导的CD4 + CD25 + foxP3 +调节性T细胞(T-regs)的诱导;能够抑制细胞毒性CD8 T细胞抗肿瘤反应的启动阶段和效应阶段以及树突状细胞成熟的缺陷;激活和抗原呈递也可能发生。还牵涉到替代激活的巨噬细胞(M2)。克服不同肿瘤所采用的这些免疫逃逸机制的策略包括使用PDT和免疫刺激治疗的联合方案,例如从致病性微生物获得的产品,哺乳动物已经针对该产品开发了识别系统,例如PAMP和Toll样受体(TLR)。本文将介绍使用CpG寡核苷酸(在细菌DNA中发现的TLR9激动剂)逆转树突状细胞功能障碍的方法,以及消除正在积极研究的T-reg的免疫抑制作用的方法。

著录项

  • 来源
    《Biophotonics and immune responses V》|2010年|P.756503.1-756503.8|共8页
  • 会议地点 San Francisco CA(US)
  • 作者单位

    Wellman Center for PhotomedicineMassachusetts General HospitalBoston MA Department of DermatologyHarvard Medical SchoolBoston MA;

    rnWellman Center for PhotomedicineMassachusetts General HospitalBoston MA Department of DermatologyHarvard Medical SchoolBoston MA Aesthetic and Plastic Center of Guangxi Medical UniversityNanningP.R China;

    rnWellman Center for PhotomedicineMassachusetts General HospitalBoston MA Department of DermatologyHarvard Medical SchoolBoston MA Harvard-MIT Division of Health Sciences and TechnologyCambridgeMA.;

  • 会议组织
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医用物理学;
  • 关键词

    photodynamic therapy; anti-tumor immunity; regulatory T-cells; CpG oligonucleotides; low dose cyclophosphamide;

    机译:光动力疗法;抗肿瘤免疫调节性T细胞; CpG寡核苷酸;低剂量环磷酰胺;
  • 入库时间 2022-08-26 14:30:56

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号